Observational study / 2020
Regular intake of glucosamine/chondroitin was linked to lower all-cause and CVD mortality in a national cohort of US adults.
Data from 16,686 NHANES participants (1999–2010) linked with mortality records were analyzed over a median follow-up of 107 months, during which 3,366 total deaths and 674 CVD deaths occurred. A total of 658 participants had taken glucosamine/chondroitin for a year or longer. In multivariable-adjusted models controlling for age, sex, race, education, smoking status, and physical activity, regular use was associated with reduced all-cause mortality (HR = 0.73; 95% CI, 0.57-0.93) and reduced CVD mortality (HR = 0.42; 95% CI, 0.23-0.75).
Shows an association, not proof of cause and effect.
- Study type
- Prospective cohort study
- Who was studied
- 16,686 US adults from NHANES (1999–2010)
- What was measured
- All-cause mortality and cardiovascular disease (CVD) mortality
THE PAPER
Glucosamine/Chondroitin and Mortality in a US NHANES Cohort.
King DE, Xiang J. J Am Board Fam Med, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.